GIP/GLP-1 dual agonist
Tirzepatide
Sold as Mounjaro, Zepbound
Tirzepatide is a dual GIP/GLP-1 receptor agonist used for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).
Compare prices →~$1010.00 / mo (generic, NADAC)
What it treats
Type 2 diabetes; chronic weight management.
Typical dosing
Weekly subcutaneous injection, titrated up.
Side effects
Nausea, diarrhea, vomiting, constipation, decreased appetite.
Interactions to know
Slows gastric emptying. Hypoglycemia risk with insulin and sulfonylureas.
Pregnancy & breastfeeding
Avoid in pregnancy.
Educational only. Not medical advice. Always confirm with your prescriber or pharmacist.